Hematology/Medical Oncology

Dr. Dan Landau has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

A new technology allows scientists to map, in single cells, the DNA binding sites of transcription factors and other regulatory proteins that control gene activity, according to a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

The ASCERTAIN V clinical trial, led by Weill Cornell Medicine researchers, demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment. 

According to a new preclinical study by Weill Cornell Medicine and MD Anderson Cancer Center investigators, colorectal tumors often find multiple ways to survive treatment, including additional genetic mutations and activation of cellular pathways typically associated with inflammation and regeneration. 

Weill Cornell Medicine faculty members were honored with awards for their exemplary achievements in medical...

The 45th annual Vincent du Vigneaud Memorial Research Symposium, a student-organized event that has become central to the Weill Cornell Graduate School of Medical Sciences experience, had a record number of 153 abstracts submitted this year, including posters and eight oral presentations.

A team of Weill Cornell Medicine investigators is working to cross-train the next generation of cancer researchers in cancer biology and the use of artificial intelligence tools for research.

Temporarily disabling a protein complex that organizes DNA into loops inside the cell’s nucleus drastically disrupted the three-dimensional structure of the genome, but surprisingly most genes continued to function as usual, Weill Cornell Medicine researchers found. 

We sat down with Dr. Jia Ruan to learn more about her clinical research and how she thinks it will help lymphoma patients.

A $1 million Research Scholar Grant from the American Cancer Society will help a multi-institution team led by Dr. Bishoy Faltas, associate professor of medicine at Weill Cornell Medicine, to develop new therapy combinations for hard-to-treat urinary tract cancers.

Six researchers from Weill Cornell Medicine have received Young Investigator Awards from the Prostate Cancer Foundation. 

An enigmatic type of circulating tumor cell called a dual-positive cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators at Weill Cornell Medicine. 

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel Deaconess Medical Center. 

A new single-cell profiling technique has mapped pre-malignant gene mutations and their effects in solid tissues for the first time, in a study led by investigators at Weill Cornell Medicine and the New York Genome Center.

A class of ultrasmall fluorescent core-shell silica nanoparticles developed at Cornell is showing an unexpected ability to rally the immune system against melanoma and dramatically improve the effectiveness of cancer immunotherapy.

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more flexible, or plastic, stem-cell-like state in the lymph nodes, according to a new preclinical study from Weill Cornell Medicine investigators. 

Dr. Despina Siolas, assistant professor of medicine at Weill Cornell Medicine, is working to personalize treatment for pancreatic cancer and develop new therapeutic regimens that save more patient lives.

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body’s immunity.

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

The way DNA folds inside the nucleus of brain cells may hold the key to understanding a devastating form of brain cancer called glioblastoma, suggests a new preclinical study from Weill Cornell Medicine researchers.